These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9875905)

  • 1. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
    Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
    Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group.
    Dhainaut JF; Tenaillon A; Le Tulzo Y; Schlemmer B; Solet JP; Wolff M; Holzapfel L; Zeni F; Dreyfuss D; Mira JP
    Crit Care Med; 1994 Nov; 22(11):1720-8. PubMed ID: 7956274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.
    Opal SM; Fisher CJ; Dhainaut JF; Vincent JL; Brase R; Lowry SF; Sadoff JC; Slotman GJ; Levy H; Balk RA; Shelly MP; Pribble JP; LaBrecque JF; Lookabaugh J; Donovan H; Dubin H; Baughman R; Norman J; DeMaria E; Matzel K; Abraham E; Seneff M
    Crit Care Med; 1997 Jul; 25(7):1115-24. PubMed ID: 9233735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis.
    Vincent JL; Spapen H; Bakker J; Webster NR; Curtis L
    Crit Care Med; 2000 Mar; 28(3):638-42. PubMed ID: 10752807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis.
    Tidswell M; Tillis W; Larosa SP; Lynn M; Wittek AE; Kao R; Wheeler J; Gogate J; Opal SM;
    Crit Care Med; 2010 Jan; 38(1):72-83. PubMed ID: 19661804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a phospholipid emulsion (GR270773) in Gram-negative severe sepsis: results of a phase II multicenter, randomized, placebo-controlled, dose-finding clinical trial.
    Dellinger RP; Tomayko JF; Angus DC; Opal S; Cupo MA; McDermott S; Ducher A; Calandra T; Cohen J;
    Crit Care Med; 2009 Nov; 37(11):2929-38. PubMed ID: 19770753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
    Eisele B; Lamy M; Thijs LG; Keinecke HO; Schuster HP; Matthias FR; Fourrier F; Heinrichs H; Delvos U
    Intensive Care Med; 1998 Jul; 24(7):663-72. PubMed ID: 9722035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis : A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial.
    Albrecht DM; van Ackern K; Bender HJ; Hof H; Kox W; Victor N; Funk P; Kieser M; Köhler S; Krausch D; Marzi I; Menges T; Schmidt H
    Clin Drug Investig; 2004; 24(3):137-47. PubMed ID: 17516700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
    Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
    Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.
    Schuster DP; Metzler M; Opal S; Lowry S; Balk R; Abraham E; Levy H; Slotman G; Coyne E; Souza S; Pribble J;
    Crit Care Med; 2003 Jun; 31(6):1612-9. PubMed ID: 12794395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators.
    Angus DC; Birmingham MC; Balk RA; Scannon PJ; Collins D; Kruse JA; Graham DR; Dedhia HV; Homann S; MacIntyre N
    JAMA; 2000 Apr; 283(13):1723-30. PubMed ID: 10755499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.
    Abraham E; Reinhart K; Svoboda P; Seibert A; Olthoff D; Dal Nogare A; Postier R; Hempelmann G; Butler T; Martin E; Zwingelstein C; Percell S; Shu V; Leighton A; Creasey AA
    Crit Care Med; 2001 Nov; 29(11):2081-9. PubMed ID: 11700399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial.
    Giamarellos-Bourboulis EJ; Mylona V; Antonopoulou A; Tsangaris I; Koutelidakis I; Marioli A; Raftogiannis M; Kopterides P; Lymberopoulou K; Mouktaroudi M; Papageorgiou C; Papaziogas B; Georgopoulou AP; Tsaganos T; Papadomichelakis E; Gogos C; Ladas M; Savva A; Pelekanou A; Baziaka F; Koutoukas P; Kanni T; Spyridaki A; Maniatis N; Pelekanos N; Kotsaki A; Vaki I; Douzinas EE; Koratzanis G; Armaganidis A
    J Antimicrob Chemother; 2014 Apr; 69(4):1111-8. PubMed ID: 24292991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels.
    Panacek EA; Marshall JC; Albertson TE; Johnson DH; Johnson S; MacArthur RD; Miller M; Barchuk WT; Fischkoff S; Kaul M; Teoh L; Van Meter L; Daum L; Lemeshow S; Hicklin G; Doig C;
    Crit Care Med; 2004 Nov; 32(11):2173-82. PubMed ID: 15640628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
    Opal S; Laterre PF; Abraham E; Francois B; Wittebole X; Lowry S; Dhainaut JF; Warren B; Dugernier T; Lopez A; Sanchez M; Demeyer I; Jauregui L; Lorente JA; McGee W; Reinhart K; Kljucar S; Souza S; Pribble J;
    Crit Care Med; 2004 Feb; 32(2):332-41. PubMed ID: 14758145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.
    Fein AM; Bernard GR; Criner GJ; Fletcher EC; Good JT; Knaus WA; Levy H; Matuschak GM; Shanies HM; Taylor RW; Rodell TC
    JAMA; 1997 Feb; 277(6):482-7. PubMed ID: 9020273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group.
    Poeze M; Froon AH; Ramsay G; Buurman WA; Greve JW
    Shock; 2000 Oct; 14(4):421-8. PubMed ID: 11049104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial.
    Lauterbach R; Pawlik D; Kowalczyk D; Ksycínski W; Helwich E; Zembala M
    Crit Care Med; 1999 Apr; 27(4):807-14. PubMed ID: 10321674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.